SCM
MGX icon

Sterling Capital Management’s Metagenomi Therapeutics MGX Stock Holding History

Sterling Capital Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-190
Closed -$258 – 3421
2025
Q1 		$258 Sell
190
-154
-45% -$367 ﹤0.01% 3056
2024
Q4 		$1.24K Buy
344
+332
+2,767% +$801 ﹤0.01% 2898
2024
Q3 		$26 Buy
+12
New +$42 ﹤0.01% 3251

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sterling Capital Management's MGX Position: Q2 2025 in Review

Sterling Capital Management sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 190 shares — an estimated $258 sold.

Sterling Capital Management first reported a position in MGX in Q3 2024 and held it in 3 quarters. The position peaked at $1.24K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Sterling Capital Management reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 190 Metagenomi Therapeutics shares in Q2 2025, an estimated $258.
  • Sterling Capital Management first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Metagenomi Therapeutics position peaked at $1.24K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.